Hiraki A, Ono T, Tanaka M, Kiura K, Ueoka H, Kawai H, Harada M, Nakayama E, Noguchi Y
Department of Immunology, Okayama University Medical School, Japan.
Anticancer Res. 2001 Jul-Aug;21(4A):2561-7.
[corrected] Non-small cell lung cancer (NSCLC) is resistant to conventional treatment; so the development of a new therapy is urgent.
50 patients with NSCLC and malignant effusion were enrolled in this study. Seventeen autologous lung cancer cell lines were established. Peripheral lymphocytes and irradiated autologous tumor cell lines were co-cultured to generate cytotoxic T lymphocytes (CTL). Expression of apoptosis-related molecules were analysed by RT-PCR or FACS.
CTL lines were established in 2 patients. Both CTL lines were CD3+, CD8+ and MHC class I-restricted T cells and showed cytotoxic activities not only against autologous tumor cell lines but against allogenic cancer cell lines. Two lung cancer cell lines were established from one patient before and after cisplatin-based chemotherapy. The tumor cell line established after chemotherapy was apoptosis-resistant, but was sensitive to cytotoxicity of CTL.
CTL-based immunotherapy may be one of the candidates for future therapies against NSCLC.
[已校正] 非小细胞肺癌（NSCLC）对传统治疗具有抗性；因此，开发新的治疗方法迫在眉睫。
本研究纳入了50例患有NSCLC和恶性胸腔积液的患者。建立了17个自体肺癌细胞系。将外周血淋巴细胞与经辐照的自体肿瘤细胞系共培养以产生细胞毒性T淋巴细胞（CTL）。通过RT-PCR或FACS分析凋亡相关分子的表达。
在2例患者中建立了CTL系。两个CTL系均为CD3 +、CD8 +且受MHC I类限制的T细胞，不仅对自体肿瘤细胞系具有细胞毒性活性，而且对同种异体癌细胞系也具有细胞毒性活性。从一名患者在基于顺铂的化疗前后建立了两个肺癌细胞系。化疗后建立的肿瘤细胞系具有抗凋亡能力，但对CTL的细胞毒性敏感。
基于CTL的免疫疗法可能是未来NSCLC治疗的候选方法之一。
